T. Rowe Price Associates’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.5M | Buy |
42,531
+36,716
| +631% | +$5.63M | ﹤0.01% | 1327 |
|
|
2025
Q4 | $803K | Sell |
5,815
-425
| -7% | -$55.7K | ﹤0.01% | 2173 |
|
|
2025
Q3 | $802K | Sell |
6,240
-300
| -5% | -$36.6K | ﹤0.01% | 2157 |
|
|
2025
Q2 | $792K | Sell |
6,540
-46,108
| -88% | -$5.2M | ﹤0.01% | 2086 |
|
|
2025
Q1 | $5.87M | Sell |
52,648
-21,240
| -29% | -$2.26M | ﹤0.01% | 1222 |
|
|
2024
Q4 | $7.19M | Sell |
73,888
-46,833
| -39% | -$4.99M | ﹤0.01% | 1196 |
|
|
2024
Q3 | $13.9M | Buy |
120,721
+113,634
| +1,603% | +$12.9M | ﹤0.01% | 1074 |
|
|
2024
Q2 | $755K | Sell |
7,087
-108,762
| -94% | -$10.9M | ﹤0.01% | 2009 |
|
|
2024
Q1 | $11.2M | Buy |
115,849
+3,696
| +3% | +$379K | ﹤0.01% | 1088 |
|
|
2023
Q4 | $11.3M | Sell |
112,153
-1,261
| -1% | -$122K | ﹤0.01% | 1071 |
|
|
2023
Q3 | $11.6M | Buy |
113,414
+6,738
| +6% | +$684K | ﹤0.01% | 1046 |
|
|
2023
Q2 | $10.8M | Buy |
106,676
+9,174
| +9% | +$918K | ﹤0.01% | 1071 |
|
|
2023
Q1 | $8.97M | Buy |
97,502
+3,673
| +4% | +$321K | ﹤0.01% | 1078 |
|
|
2022
Q4 | $8.51M | Sell |
93,829
-774
| -0.8% | -$65.2K | ﹤0.01% | 1084 |
|
|
2022
Q3 | $13.3M | Buy |
94,603
+53,220
| +129% | +$4.41M | ﹤0.01% | 1012 |
|
|
2022
Q2 | $3.5M | Buy |
41,383
+1,881
| +5% | +$165K | ﹤0.01% | 1473 |
|
|
2022
Q1 | $3.47M | Buy |
39,502
+5,293
| +15% | +$458K | ﹤0.01% | 1542 |
|
|
2021
Q4 | $2.99M | Buy |
34,209
+890
| +3% | +$73.9K | ﹤0.01% | 1585 |
|
|
2021
Q3 | $2.72M | Buy |
33,319
+2,691
| +9% | +$242K | ﹤0.01% | 1626 |
|
|
2021
Q2 | $2.79M | Buy |
30,628
+3,063
| +11% | +$273K | ﹤0.01% | 1632 |
|
|
2021
Q1 | $2.36M | Sell |
27,565
-671
| -2% | -$60.2K | ﹤0.01% | 1659 |
|
|
2020
Q4 | $2.08M | Sell |
28,236
-596,750
| -95% | -$52.1M | ﹤0.01% | 1623 |
|
|
2020
Q3 | $54.3M | Buy |
624,986
+358,726
| +135% | +$31.1M | 0.01% | 839 |
|
|
2020
Q2 | $23.3M | Sell |
266,260
-130,456
| -33% | -$11.3M | ﹤0.01% | 1107 |
|
|
2020
Q1 | $32.7M | Buy |
396,716
+304,665
| +331% | +$27.2M | 0.01% | 918 |
|
|
2019
Q4 | $8.72M | Buy |
92,051
+63,914
| +227% | +$5.73M | ﹤0.01% | 1335 |
|
|
2019
Q3 | $2.44M | Sell |
28,137
-1,800
| -6% | -$162K | ﹤0.01% | 1528 |
|
|
2019
Q2 | $2.73M | Sell |
29,937
-2,949
| -9% | -$250K | ﹤0.01% | 1500 |
|
|
2019
Q1 | $2.83M | Buy |
32,886
+90
| +0.3% | +$7.22K | ﹤0.01% | 1498 |
|
|
2018
Q4 | $2.52M | Sell |
32,796
-5,580
| -15% | -$434K | ﹤0.01% | 1504 |
|
|
2018
Q3 | $2.96M | Sell |
38,376
-1,214
| -3% | -$89.7K | ﹤0.01% | 1531 |
|
|
2018
Q2 | $2.68M | Sell |
39,590
-3,672
| -8% | -$253K | ﹤0.01% | 1529 |
|
|
2018
Q1 | $3.13M | Buy |
43,262
+8,707
| +25% | +$663K | ﹤0.01% | 1488 |
|
|
2017
Q4 | $2.6M | Buy |
34,555
+12,125
| +54% | +$915K | ﹤0.01% | 1527 |
|
|
2017
Q3 | $1.73M | Sell |
22,430
-67
| -0.3% | -$5.06K | ﹤0.01% | 1608 |
|
|
2017
Q2 | $1.68M | Hold |
22,497
| – | – | ﹤0.01% | 1597 |
|
|
2017
Q1 | $1.5M | Sell |
22,497
-1,552
| -6% | -$103K | ﹤0.01% | 1658 |
|
|
2016
Q4 | $1.57M | Sell |
24,049
-326
| -1% | -$21.1K | ﹤0.01% | 1619 |
|
|
2016
Q3 | $1.73M | Buy |
24,375
+1,440
| +6% | +$105K | ﹤0.01% | 1574 |
|
|
2016
Q2 | $1.7M | Buy |
22,935
+480
| +2% | +$33.2K | ﹤0.01% | 1561 |
|
|
2016
Q1 | $1.46M | Sell |
22,455
-1,827
| -8% | -$124K | ﹤0.01% | 1600 |
|
|
2015
Q4 | $1.87M | Hold |
24,282
| – | – | ﹤0.01% | 1542 |
|
|
2015
Q3 | $2M | Sell |
24,282
-378,882
| -94% | -$33.7M | ﹤0.01% | 1547 |
|
|
2015
Q2 | $35.5M | Sell |
403,164
-4,352
| -1% | -$399K | 0.01% | 954 |
|
|
2015
Q1 | $36M | Buy |
407,516
+6,528
| +2% | +$579K | 0.01% | 947 |
|
|
2014
Q4 | $33.3M | Sell |
400,988
-4,687
| -1% | -$389K | 0.01% | 979 |
|
|
2014
Q3 | $34.2M | Sell |
405,675
-855,883
| -68% | -$69.2M | 0.01% | 955 |
|
|
2014
Q2 | $102M | Buy |
1,261,558
+1,243,247
| +6,790% | +$97.8M | 0.02% | 627 |
|
|
2014
Q1 | $1.4M | Hold |
18,311
| – | – | ﹤0.01% | 1621 |
|
|
2013
Q4 | $1.32M | Buy |
18,311
+120
| +0.7% | +$8.34K | ﹤0.01% | 1621 |
|
|
2013
Q3 | $1.25M | Sell |
18,191
-167
| -0.9% | -$11K | ﹤0.01% | 1630 |
|
|
2013
Q2 | $1.16M | Buy |
+18,358
| New | +$1.19M | ﹤0.01% | 1622 |
|
Other funds holding NVS
T. Rowe Price Associates's NVS Position: Q1 2026 in Review
T. Rowe Price Associates increased its Novartis (NVS) stake by 631% in Q1 2026, buying an estimated $5.63M and bringing the position to 42,531 shares worth $6.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1327.
T. Rowe Price Associates first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $102M in Q2 2014. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- T. Rowe Price Associates held 42,531 shares of Novartis worth $6.5M as of Q1 2026.
- T. Rowe Price Associates bought 36,716 Novartis shares in Q1 2026, an estimated $5.63M.
- Novartis made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1327 holding.
- T. Rowe Price Associates first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Novartis position peaked at $102M in Q2 2014.
- 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.